L-655238

Names

[ CAS No. ]:
101910-24-1

[ Name ]:
L-655238

[Synonym ]:
rev-5901
rg 5901
Benzenemethanol, α-pentyl-3-(2-quinolinylmethoxy)-
1-[3-(2-Quinolinylmethoxy)phenyl]-1-hexanol
pf 5901
1-[3-(Quinolin-2-ylmethoxy)phenyl]hexan-1-ol

Biological Activity

[Description]:

REV 5901 is a competitive and orally active antagonist of leukotriene receptor, with a Ki of 0.7 μM. REV 5901 is also a 5-lipoxygenase inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved[1][2].

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> Leukotriene Receptor

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Metabolic Enzyme/Protease >> 5-Lipoxygenase

[Target]

Ki: 0.7 μM (leukotriene receptor)[1] [2]

[References]

[1]. Inwegen RGV, et, al. REV 5901: an orally effective peptidoleukotriene antagonist, detailed biochemical/pharmacological profile. J Pharmacol Exp Ther. 1987 Apr;241(1):117-24.

[2]. Anderson G, et, al. Effects of REV 5901, a 5-lipoxygenase inhibitor and leukotriene antagonist, on pulmonary responses to platelet activating factor in the guinea-pig. Br J Pharmacol. 1988 Aug;94(4):1115-22.

Chemical & Physical Properties

[ Density]:
1.1±0.1 g/cm3

[ Boiling Point ]:
497.7±35.0 °C at 760 mmHg

[ Molecular Formula ]:
C₂₂H₂₅NO₂

[ Molecular Weight ]:
335.439

[ Flash Point ]:
254.8±25.9 °C

[ Exact Mass ]:
335.188538

[ PSA ]:
42.35000

[ LogP ]:
4.94

[ Vapour Pressure ]:
0.0±1.3 mmHg at 25°C

[ Index of Refraction ]:
1.606

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xi

[ Risk Phrases ]:
R36/37/38

[ Safety Phrases ]:
26-36

[ RIDADR ]:
NONH for all modes of transport

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Articles

Early vascular permeability in murine experimental peritonitis is co-mediated by resident peritoneal macrophages and mast cells: crucial involvement of macrophage-derived cysteinyl-leukotrienes.

Inflammation 26(2) , 61-71, (2002)

The initial phase of zymosan-induced peritonitis involves an increase of vascular permeability (peak at 30 min) that is correlated with high levels of vasoactive eicosanoids, namely, prostaglandins (P...

Actions of cysteinyl leukotrienes in the enteric nervous system of guinea-pig stomach and small intestine.

Eur. J. Pharmacol. 459(1) , 27-39, (2003)

Conventional intracellular microelectrodes, neuronal tracer injection techniques and immunohistochemistry were used to study the actions of cysteinyl leukotrienes (CysLTs) on electrical and synaptic b...

Enhanced activity of Ca2+-activated K+ channels by 1-[2-hydroxy-3-propyl-4-[(1H-tetrazol-5-yl)butoxyl]phenyl] ethanone (LY-171883) in neuroendocrine and neuroblastoma cell lines.

J. Cell Physiol. 192(2) , 188-99, (2002)

The effects of LY-171883, an orally active leukotriene antagonist, on membrane currents were examined in pituitary GH(3) and in neuroblastoma IMR-32 cells. In GH(3) cells, LY-171883 (1-300 microM) rev...